Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of JPY 319.82 billion. The enterprise value is 602.12 billion.

Market Cap	319.82B
Enterprise Value	602.12B

Important Dates

The last earnings date was Tuesday, May 13, 2025.

Earnings Date	May 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Sumitomo Pharma has 397.29 million shares outstanding.

Current Share Class	397.29M
Shares Outstanding	397.29M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.03%
Owned by Institutions (%)	15.09%
Float	180.16M

Valuation Ratios

The trailing PE ratio is 13.53 and the forward PE ratio is 9.95.

PE Ratio	13.53
Forward PE	9.95
PS Ratio	0.80
PB Ratio	1.89
P/TBV Ratio	n/a
P/FCF Ratio	39.97
P/OCF Ratio	19.38
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.98, with an EV/FCF ratio of 75.25.

EV / Earnings	25.48
EV / Sales	1.51
EV / EBITDA	15.98
EV / EBIT	49.69
EV / FCF	75.25

Financial Position

The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.80.

Current Ratio	1.05
Quick Ratio	0.42
Debt / Equity	1.80
Debt / EBITDA	7.92
Debt / FCF	38.17
Interest Coverage	0.96

Financial Efficiency

Return on equity (ROE) is 14.52% and return on invested capital (ROIC) is 1.55%.

Return on Equity (ROE)	14.52%
Return on Assets (ROA)	0.99%
Return on Invested Capital (ROIC)	1.55%
Return on Capital Employed (ROCE)	2.59%
Revenue Per Employee	80.09M
Profits Per Employee	4.75M
Employee Count	4,980
Asset Turnover	0.48
Inventory Turnover	1.46

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +143.36% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+143.36%
50-Day Moving Average	715.56
200-Day Moving Average	632.74
Relative Strength Index (RSI)	55.06
Average Volume (20 Days)	19,830,450

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of JPY 398.83 billion and earned 23.63 billion in profits. Earnings per share was 59.49.

Revenue	398.83B
Gross Profit	245.40B
Operating Income	13.02B
Pretax Income	17.61B
Net Income	23.63B
EBITDA	38.59B
EBIT	13.02B
Earnings Per Share (EPS)	59.49

Full Income Statement

Balance Sheet

The company has 23.12 billion in cash and 305.42 billion in debt, giving a net cash position of -282.31 billion or -710.58 per share.

Cash & Cash Equivalents	23.12B
Total Debt	305.42B
Net Cash	-282.31B
Net Cash Per Share	-710.58
Equity (Book Value)	169.48B
Book Value Per Share	426.59
Working Capital	12.57B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 16.50 billion and capital expenditures -8.50 billion, giving a free cash flow of 8.00 billion.

Operating Cash Flow	16.50B
Capital Expenditures	-8.50B
Free Cash Flow	8.00B
FCF Per Share	20.14

Full Cash Flow Statement

Margins

Gross margin is 61.53%, with operating and profit margins of 3.27% and 5.93%.

Gross Margin	61.53%
Operating Margin	3.27%
Pretax Margin	4.42%
Profit Margin	5.93%
EBITDA Margin	9.67%
EBIT Margin	3.27%
FCF Margin	2.01%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.01%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	7.39%
FCF Yield	2.50%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 0.93. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.93
Piotroski F-Score	n/a